{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "22002072",
  "DateCompleted": {
    "Year": "2012",
    "Month": "04",
    "Day": "09"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "10",
    "Day": "20"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1007/s10072-011-0795-x"
    ],
    "Journal": {
      "ISSN": "1590-3478",
      "JournalIssue": {
        "Volume": "32 Suppl 2",
        "PubDate": {
          "Year": "2011",
          "Month": "Nov"
        }
      },
      "Title": "Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology",
      "ISOAbbreviation": "Neurol Sci"
    },
    "ArticleTitle": "Lecture: management of chemotherapy-induced febrile neutropenia; guidelines and colony stimulating factors.",
    "Pagination": {
      "StartPage": "S217",
      "EndPage": "S219",
      "MedlinePgn": "S217-9"
    },
    "Abstract": {
      "AbstractText": [
        "Chemotherapy-induced febrile neutropenia (FN) is a major risk factor for severe infections potentially fatal, and also a dose-limiting toxicity, so causing dose reductions and/or delays in scheduled chemotherapy. This lecture provides recommendations for the use of G-CSF in adult cancer patients at risk of chemotherapy-induced FN. If expected risk of FN is equal or superior to 20%, a primary prophylaxis of FN with G-CSF is recommended. Primary prophylaxis can be considered in case of intermediate 10-20% risk of FN, in presence of factors that increase the frequency/risk of FN, such as age >65, advanced disease, prior episode of FN, poor performance status, radiotherapy to a wide body area (>20%). In case of low risk of FN (<10%), primary prophylaxis is not recommended. We also described the differences in potency and efficacy between two G-CSF, lenograstim (glycosylated) and filgrastim (non-glycosylated), which should be considered when deciding the G-CSF for each patient, particularly in high risk settings for FN."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Fondazione IRCCS-Istituto Nazionale Tumori, Milan, Italy. Giuseppe.Procopio@istitutotumori.mi.it"
          }
        ],
        "LastName": "Procopio",
        "ForeName": "Giuseppe",
        "Initials": "G"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Niger",
        "ForeName": "Monica",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Testa",
        "ForeName": "Isabella",
        "Initials": "I"
      }
    ],
    "PublicationTypeList": [
      "Lecture"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Italy",
    "MedlineTA": "Neurol Sci",
    "NlmUniqueID": "100959175",
    "ISSNLinking": "1590-1874"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Adjuvants, Immunologic"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antineoplastic Agents"
    },
    {
      "RegistryNumber": "143011-72-7",
      "NameOfSubstance": "Granulocyte Colony-Stimulating Factor"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Adjuvants, Immunologic"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Aged"
    },
    {
      "QualifierName": [
        "adverse effects"
      ],
      "DescriptorName": "Antineoplastic Agents"
    },
    {
      "QualifierName": [
        "chemically induced",
        "complications",
        "prevention & control"
      ],
      "DescriptorName": "Fever"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Glycosylation"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Granulocyte Colony-Stimulating Factor"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Guidelines as Topic"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [
        "blood",
        "drug therapy"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [
        "chemically induced",
        "complications",
        "prevention & control"
      ],
      "DescriptorName": "Neutropenia"
    }
  ]
}